In an announcement that caught observers off-guard over the weekend, the sponsor for the phase III OCEANIC-AF trial comparing up-and-comer asundexian against apixaban in patients with atrial ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

Cumulative safety data from three trials testing the reversible direct factor XIa inhibitor asundexian in patients at risk for stroke or recurrent cardiovascular events suggest a better bleeding ...

Bayer (XTRA:BAYN) has received validation from the European Medicines Agency for the marketing application of its oral Factor XIa inhibitor, asundexian, for stroke prevention. Asundexian is also under ...

Add Yahoo as a preferred source to see more of our stories on Google. The study compared asundexian 50mg plus antiplatelet therapy to placebo in post-ischaemic stroke or high-risk TIA patients. Credit ...

OCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without increasing ISTH major bleeding rate, compared to placebo ...

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third ...

(RTTNews) - Bayer AG (BAYZF.PK) late Sunday announced positive topline results from Phase III OCEANIC-STROKE study with its investigational, once daily, oral FXIa inhibitor asundexian, in secondary ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor ...